sb 203580 has been researched along with exenatide in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (exenatide) | Trials (exenatide) | Recent Studies (post-2010) (exenatide) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 2,806 | 383 | 2,016 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chang, G; Li, Y; Lu, K; Ye, L; Zhang, D; Zhang, P | 1 |
1 other study(ies) available for sb 203580 and exenatide
Article | Year |
---|---|
Protective effects of extendin‑4 on hypoxia/reoxygenation‑induced injury in H9c2 cells.
Topics: Adenosine Triphosphate; Animals; Cell Hypoxia; Cell Line; Cell Survival; Creatine Kinase, MB Form; Enzyme-Linked Immunosorbent Assay; Exenatide; Glucose; Glucose Transporter Type 1; Imidazoles; Intercellular Signaling Peptides and Proteins; L-Lactate Dehydrogenase; Mitogen-Activated Protein Kinase 12; Myocytes, Cardiac; Naphthalenes; Peptides; Protective Agents; Proteins; Pyrazoles; Pyridines; Rats; Signal Transduction; Venoms | 2015 |